PA
STGW icon

PharVision Advisers’s Stagwell STGW Stock Holding History

PharVision Advisers’s Portfolio STGW Stock Details STGW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,298
Closed -$117K – 422
2025
Q1 		$117K Buy
19,298
+360
+2% +$2.26K 0.16% 241
2024
Q4 		$125K Buy
+18,938
New +$135K 0.11% 363

Other funds holding STGW

Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PharVision Advisers's STGW Position: Q2 2025 in Review

PharVision Advisers sold out of Stagwell (STGW) in Q2 2025, closing a stake of 19,298 shares — an estimated $117K sold.

PharVision Advisers first reported a position in STGW in Q4 2024 and held it in 2 quarters. The position peaked at $125K in Q4 2024. 153 funds tracked by Wall St. Rank hold STGW as of Q2 2025.

  • PharVision Advisers reported no remaining Stagwell position as of Q2 2025 after selling out during the quarter.
  • PharVision Advisers sold 19,298 Stagwell shares in Q2 2025, an estimated $117K.
  • PharVision Advisers first reported a position in Stagwell in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's Stagwell position peaked at $125K in Q4 2024.
  • 153 funds tracked by Wall St. Rank held Stagwell as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.